Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Kyntra Bio, Inc. (NASDAQ: KYNB) is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics based on circadian biology. The company operates within the biopharmaceutical and life sciences industries, with a particular emphasis on diseases where circadian rhythm disruption plays a role, including oncology and immune-related conditions. Kyntra Bio does not currently generate commercial revenue and is primarily funded through equity financing and public market capital.
The company’s core business centers on developing small-molecule drug candidates that modulate circadian clock pathways, with its lead programs targeting cryptochrome (CRY) proteins. Kyntra Bio positions itself as a specialist in an emerging and differentiated area of drug discovery, aiming to address unmet medical needs through first-in-class or best-in-class mechanisms. The company was founded in 2017 and became publicly listed through a reverse merger transaction, subsequently rebranding as Kyntra Bio, Inc.
Business Operations
Kyntra Bio’s operations are organized around drug discovery and preclinical/clinical development, with internal capabilities focused on research, early-stage development, and regulatory planning. The company’s lead development candidate, KYN-547, is a small-molecule CRY inhibitor designed to modulate circadian rhythm pathways and is being evaluated for potential applications in oncology and immune-mediated diseases. As of the most recent public disclosures, Kyntra Bio remains in the clinical or advanced preclinical development stage.
The company operates primarily in the United States and relies on a combination of in-house scientific leadership and third-party contract research organizations for laboratory research, toxicology studies, and manufacturing support. Kyntra Bio does not report any commercial subsidiaries or revenue-generating joint ventures, and its business model is focused on advancing assets to value-inflection points that could support partnerships or later-stage development.
Strategic Position & Investments
Kyntra Bio’s strategic direction centers on advancing its circadian biology pipeline through early clinical development while preserving capital efficiency. Growth initiatives are primarily research-driven, with investments allocated toward clinical trials, intellectual property protection, and expansion of its circadian-focused drug discovery platform. The company has emphasized disciplined capital deployment due to its status as a development-stage biotech with limited operating history.
The company has not disclosed any major acquisitions or large-scale equity investments in external companies. Its strategic assets consist mainly of internally developed intellectual property, proprietary compounds, and know-how related to circadian rhythm modulation. Emerging areas of focus include the role of circadian disruption in cancer biology and immune regulation, though the ultimate clinical and commercial impact of these programs remains to be established.
Geographic Footprint
Kyntra Bio is headquartered in San Diego, California, a major U.S. biotechnology hub, and conducts the majority of its operations within the United States. Its geographic footprint is relatively concentrated, reflecting its size and development-stage focus. Research and development activities are supported through domestic facilities and U.S.-based third-party service providers.
While the company does not currently maintain significant international operations or offices, its clinical development strategy may involve international trial sites as programs advance. Any broader global commercial presence would be contingent on successful clinical outcomes and future partnerships.
Leadership & Governance
Kyntra Bio is led by an executive team with experience in biotechnology research, drug development, and public company management. The company emphasizes a science-driven leadership philosophy focused on disciplined execution, capital stewardship, and advancing differentiated therapeutic approaches.
Key executives include:
- Mark D. Glover – Chief Executive Officer
- Brian Ritchie – Chief Financial Officer
- Data inconclusive based on available public sources regarding additional executive officers and their current titles
The board of directors provides oversight consistent with U.S. public company governance standards, with committees addressing audit, compensation, and corporate governance matters.